HAVCR1 Polyclonal antibody
HAVCR1 Polyclonal Antibody for ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (1)
Applications
IF, IHC, ELISA
Conjugate
Unconjugated
Cat no : 26420-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Recommended dilution
Application | Dilution |
---|---|
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
IHC | See 1 publications below |
IF | See 1 publications below |
Product Information
The immunogen of 26420-1-AP is HAVCR1 Fusion Protein expressed in E. coli.
Tested Reactivity | human |
Cited Reactivity | mouse |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | HAVCR1 fusion protein Ag23888 相同性解析による交差性が予測される生物種 |
Full Name | hepatitis A virus cellular receptor 1 |
Calculated molecular weight | 359 aa, 39 kDa |
GenBank accession number | BC013325 |
Gene symbol | HAVCR1 |
Gene ID (NCBI) | 26762 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Hepatitis A virus cellular receptor 1 (HAVCR1, also known as TIM-1, KIM-1 or CD365) is a class I integral membrane glycoprotein, with an ectodomain containing Ig-like domain and a mucin domain. HAVCR1 acts as a membrane receptor for hepatitis A virus (HHAV) (PMID: 9658108; 8861957). HAVCR1 provides a costimulatory signal for T cell activation and inhibits the development of peripheral tolerance (PMID: 16284246; 15793575). HAVCR1 may be involved in the regulation of asthma and allergic diseases (PMID: 14534576). It has been reported that HAVCR1 is shed into urine after acute kidney damage and is a marker of renal tubular injury (PMID: 14600030).
Publications
Species | Application | Title |
---|---|---|
Drug Deliv Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury. |